semaglutide 2 mg
Despite The Odds, Prescription Weight Loss Triumphs Over Tirzepatide
In real-world studies, 48% of patients on semaglutide 2 mg achieve HbA1c < 7% within six months, showing prescription weight-loss therapy can beat tirzepatide. This outcome reflects larger weight loss and better adherence seen across large observational cohorts, shifting clinical preference toward the higher-dose GLP-1 agent. Medical Disclaimer: This article